Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical trial results. Zepound manufacturer Eli Lilly released results from ...

For Debbie Halstead, the weight loss medication Wegovy has been nothing short of a miracle. The Cool Ridge, West Virginia, woman shed 60 pounds and lowered her blood pressure nearly 60 points.

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial ...

Lilly's Zepbound shows 47% more weight loss than Wegovy in trial First study comparing the drugs under same trial parameters Novo to wait for full trial data, flags Wegovy's heart benefits The U.S ...

Lilly officials said 31% of people taking Zepbound lost at least 25% of their body weight compared to 16% of study participants who took Wegovy. Experts note that weight loss drugs can only be ...

In the 751-person trial, Zepbound helped patients lose an average of 20% of their weight after 72 weeks compared to 14% for the group treated with Wegovy, Lilly said. Participants were either ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to ...